A cell therapy for liver cancer that has progressed on other treatments
Part of Cancer clinical trials.
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your liver cancer must be advanced and have a protein called GPC3 on the tumor cells (a lab test will check this).
- You must be between 18 and 75 years old.
- Your cancer must have gotten worse or you couldn't tolerate at least one standard treatment (like chemotherapy or targeted therapy).
- Your liver function must be fairly good (Child-Pugh score 7 or less) and your blood counts and kidney function must meet certain levels.
- You cannot have had certain other cancer treatments too recently, or have active brain tumors, severe heart disease, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called Super CAR-T for people with advanced liver cancer that has GPC3 protein. It aims to see if the treatment is safe and effective. You may be eligible if your cancer has not responded to or stopped working on at least two standard treatments.
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
This trial tests a new type of cell therapy called C-CAR031, which is designed to target and attack liver cancer cells that have a protein called GPC3. It is for people with advanced liver cancer who have already tried other treatments and are looking for a new option.
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
This trial tests a new type of immune cell therapy called Metabolically Armed GPC3 CAR-T cells (Meta10-GPC3) for people with liver cancer that has come back or spread and cannot be removed by surgery. The cells are designed to target a protein called GPC3 on cancer cells and may help shrink tumors.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.